PRESS RELEASE

Clinical Network Services (CNS) participates in panel at 13th Annual Phacilitate Vaccine Forum

Brisbane, Australia- 20th January 2014 - Clinical Network Services (CNS) an integrated product development company based in Australia and New Zealand providing broad services in the planning, implementation and delivery of preclinical, Phase 1 and 2 trials, today announced that it will participate in a panel at the 13th Annual Phacilitate Vaccine Forum, part of the Washington BioLeaders Forum conference, to be held January 27-29, 2014, at Grand Hyatt Washington, DC, USA.

Mark Reid, Associate Director, BioDesk & Regulatory Affairs at CNS, will participate in a panel discussion entitled "Emerging pathogens: How to face the latest wave of ID threats with the benefit of past experience - Government, regulator and industry perspectives" at 2.35pm on Monday 27 January. The panel will include:

Dr Marion Gruber, Director, Office of Vaccines Research & Review, US FDA
Dr Gregory M. Glenn, Senior Vice President & Chief Medical Officer, Novavax
Dr Richard Kenney, CMO, Immune Design Corp.
Andrew Geall, PhD, RNA Vaccine Platform Technology Leader, Novartis Vaccines and Diagnostics
Mark Reid, Associate Director, BioDesk & Regulatory Affairs, Clinical Network Services
Dr Liz Pollitt, Senior Consultant, NDA Group

The event will cover a range of topics relating to the regulation of vaccines in clinical trials.

"I am really looking forward to participating in this leading industry forum," commented Mark Reid, "since CNS has a particular strength in vaccine product development right from conception with our BioDesk consultancy through Phase I and II clinical trials"

The 13th Annual Phacilitate Vaccine Forum will provide a highly valuable, all-plenary meeting place for senior level industry and public sector figures driving the development and manufacture of novel vaccines on a global scale. Firmly focused on translating unmet medical need into national and global public health benefit, the organisers expect 500-600 attendees from industry.

Mark Reid will also be available through the conference partnering system to meet with vaccine developers interested in CNS' product development planning, preclinicial and clinical services.

- ends -

About Clinical Network Services
Clinical Network Services (CNS) Pty Ltd is an Australian, New Zealand and UK CRO offering integrated development services to virtual, small and medium sized Biotech companies in the planning, implementation and delivery of Phase 1 and 2 trials, and beyond. CNS offers a unique service where it integrates **BioDesk,** an intelligent product development planning and regulatory affairs service, with our committed, highly experienced regional clinical operations team. Our "Regional Advantage" is driven by our extremely pragmatic regulatory environment that makes it possible for our clients to enter the clinic quickly, without the need for prior approval from another regulatory agency. Specifically, **BioDesk** works

closely with our clients to design, implement and manage manufacturing and preclinical plans that are always mindful of commercial timelines and budgets, allowing swifter go/no go decisions for our clients and their investors. With operations across Australia and New Zealand, CNS makes use of its close relationships with key opinion leaders, world leading clinical facilities, and globally respected Phase I units across a wide variety of therapeutic indications. Our service offerings include: product development and regulatory affairs planning and development, clinical planning and study start up, monitoring, project management, data management/biostatistics, medical consultancy/monitoring, medical writing, bioanalytical services and safety reporting.

Further information on CNS can be found at www.clinical.net.au

Contact:

Clinical Network Services	College Hill Life Sciences
Russell Neal T: +61 (0)7 3719 6000 russell.neal[at]clinical.net.au	Dr. Douglas Pretsell T: +61 (0)466 925 966 douglas.pretsell[at]collegehill.com

Notes for editors

About BioDesk
BioDesk is a unique global product development and regulatory planning consultancy which assists Biotech companies get into the clinic faster through creating and managing a pre-clinical programme that encompasses a globalised regulatory perspective whilst leveraging unique regional advantages.

Specifically, BioDesk works closely with our clients to design, implement and manage manufacturing and pre-clinical plans mindful of commercial timelines and budgets, allowing swifter go/no go decisions for our clients and their investors.

Services offered by BioDesk include:

- Developing a forward looking Product (Drug) Development Plan
- Supporting the aggregation of pre-clinical chemistry, GMP and CMC
- Formulating development plans appropriate to venture capitalists and regulators
- Strategic regulatory advice for key international and local markets
- Support and development of regulatory submissions such as INDs, CTAs, BLAs, MLAs, etc.
- Project and programme management.

Through BioDesk, CNS offers the Biotech industry a focused approach to biotherapeutic development. When coupled with our clinical management expertise, our approach drives efficient navigation through the critical period of post-discovery planning and initial clinic testing whilst adding value to the global dossier and delivering improved commercial outcomes to our clients.